Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula|||0000-0002-6871-0098
  • Navarro, Jordi|||0000-0002-7187-0367
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • García Pérez, Jorge Néstor|||0000-0003-4986-6094
  • Descalzo Jorro, Vicente
  • Monforte-Pallarés, Arnau|||0000-0002-5468-3885
  • Arando, Maider|||0000-0003-2020-4193
  • Rodríguez Vázquez, Lucía|||0000-0003-0151-3142
  • Planas, Bibiana|||0000-0002-1490-7127
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Curran, Adrian|||0000-0002-1263-0814
  • Buzón, Maria José|||0000-0003-4427-9413
  • Falcó, Vicenç|||0000-0001-9626-0023
Objectives: We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods: Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results: ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions: The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early antiretroviral therapy shapes the immunometabolic landscape without reducing the intact HIV reservoir

  • Suanzes, Paula|||0000-0002-6871-0098
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Navarro, Jordi|||0000-0002-7187-0367
  • Chafino, Silvia
  • Rull, Anna|||0000-0002-8907-7754
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Descalzo Jorro, Vicente
  • García Pérez, Jorge Néstor|||0000-0003-4986-6094
  • Monforte-Pallarés, Arnau|||0000-0002-5468-3885
  • Curran, Adrian|||0000-0002-1263-0814
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Planas, Bibiana|||0000-0002-1490-7127
  • Sanchiz Cruz, Marta|||0000-0002-6727-428X
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
Objectives: We assessed the effect of early ART during acute HIV infection on reservoir dynamics, cytokine profile, and T-cell metabolism. Methods: We studied a longitudinal cohort of PWH starting ART during early (ET) or chronic (CT) infection, and a cross-sectional cohort including matched ET and CT participants (≥36 months virologically suppressed) and HIV-negative controls. We analysed total HIV-DNA, intact and defective proviruses, cell-associated HIV-RNA, plasma cytokines, and metabolomic profiles of CD4+ and CD8+T-cells. Results: Over 75% of ET participants started ART in Fiebig stages IV-VI. Early ART was associated with lower total HIV-DNA and cell-associated RNA. Although intact proviruses were similar between groups, they represented a larger proportion of the reservoir in ET participants. Worse pre-ART immune status correlated with a larger and more transcriptionally active reservoir. Regulatory, inflammatory, and homeostatic cytokines negatively correlated with the intact reservoir, particularly in CT participants. Metabolomic profiling of T-cells demonstrated ART timing-dependent alterations in several metabolic pathways. Metabolites involved in glycolysis, amino-acid metabolism, and polyol pathways positively correlated with HIV transcription in CD4⁺T-cells, especially in CT participants. Conclusion: Early ART limits the HIV reservoir size, shapes its composition, and influences immunometabolic pathways, though it might not be enough to reduce the intact reservoir.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula
  • Álvarez-López, Patricia
  • García Pérez, Jorge N.
  • Monforte, Arnau
  • Arando Lasagabaster, Maider
  • Rodríguez Vázquez, Lucía
  • Planas Ribas, Bibiana
  • Curran Fàbregas, Adria
  • Navarro, Jordi
  • Rando Segura, Ariadna
  • Descalzo Jorro, Vicente
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Burgos Cibrian, Joaquin
Acute HIV infection; Antiretroviral treatment; Immune recovery, Infección aguda por VIH; Tratamiento antirretroviral; Recuperación inmunitaria, Infecció aguda per VIH; Tractament antiretroviral; Recuperació immunitària, Objectives We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens., This work was founded by Instituto de Salud Carlos III (Acción Estratégica en Salud) and Fondo Europeo de Desarrollo Regional (FEDER) through grant PI20/00823. The study was also supported by the Spanish Network for AIDS Research (RIS) through the Instituto de Salud Carlos III – Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER). For this project, PS has received a grant from the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC) funded by ViiV Healthcare. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). The funders had no role in the study design, data collection, and interpretation, or the decision to submit the work for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula
  • Álvarez-López, Patricia
  • García Pérez, Jorge N.
  • Monforte, Arnau
  • Arando Lasagabaster, Maider
  • Rodríguez Vázquez, Lucía
  • Planas Ribas, Bibiana
  • Curran Fàbregas, Adria
  • Navarro, Jordi
  • Rando Segura, Ariadna
  • Descalzo Jorro, Vicente
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Burgos Cibrian, Joaquin
Acute HIV infection; Antiretroviral treatment; Immune recovery, Infección aguda por VIH; Tratamiento antirretroviral; Recuperación inmunitaria, Infecció aguda per VIH; Tractament antiretroviral; Recuperació immunitària, Objectives We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens., This work was founded by Instituto de Salud Carlos III (Acción Estratégica en Salud) and Fondo Europeo de Desarrollo Regional (FEDER) through grant PI20/00823. The study was also supported by the Spanish Network for AIDS Research (RIS) through the Instituto de Salud Carlos III – Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER). For this project, PS has received a grant from the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC) funded by ViiV Healthcare. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). The funders had no role in the study design, data collection, and interpretation, or the decision to submit the work for publication.